Please login to the form below
lenvatinib
This page shows the latest lenvatinib news and features for those working in and with pharma, biotech and healthcare.
Roche’s Tecentriq/Avastin combo improves survival in liver cancer
Merck is testing Keytruda alongside partner Eisai’s kinase inhibitor Lenvima (lenvatinib) – already-approved for first-line HCC – in the Leap-002 trial, picking up a breakthrough designation from the FDA
Latest news
-
Merck CFO: we’re not only about Keytruda
He said the performance of other cancer drugs like Lenvima (lenvatinib) and Lynparza (olaparib), revenue from which doubled in the quarter – as well as the vaccine portfolio headed by cervical cancer
-
Merck says it has plenty in the pipe beyond Keytruda
AstraZeneca-partnered Lynparza (olaparib) and Eisai-partnered Lenvima (lenvatinib) that the company is also expecting to show significant growth in the coming years.
-
Analysts look beyond Keytruda in Merck’s future
Human papillomavirus (HPV) vaccine Gardasil was up a third to $835m, and there were good performances for cancer drugs Lynparza (olaparib) and Lenvima (lenvatinib), partnered with AstraZeneca and Eisai, respectively.
-
Pfizer’s plans for Inlyta go awry with failed adjuvant trial
nivolumab) and Exelixis’ multikinase inhibitor Cabometyx (cabozantinib) - backed by strong overall survival data - as well as Eisai’s multikinase drug Lenvima (lenvatinib).
-
$5.76bn deal puts Merck closer to Eisai and fast-growing Lenvima
rights for Lenvima (lenvatinib) and start a series of clinical trials in combination with Keytruda (pembrolizumab).
More from news
Approximately 2 fully matching, plus 18 partially matching documents found.
Latest Intelligence
-
Eisai: Bucking the trend with R&D growth
The monoclonal antibody farletuzumab is in phase III trials for ovarian cancer, and has reached the phase II stage for non-small cell lung cancer, while lenvatinib is also in phase
More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.
COVID-19 Updates and Daily News
Featured jobs
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- GSK plans to produces one billion doses of vaccine adjuvant for COVID-19
- EMA clears BMS’ oral multiple sclerosis drug Zeposia
- Roche/Gilead tag team fights COVID-19 with Actemra/remdesivir
- Merck’s Keytruda hits the mark in triple negative breast cancer
- Finalists 2020 - Communiqué Awards
- ASCO: Momentum gathers behind next wave of CAR-T therapies
- Lilly starts world first trial of an antibody drug for COVID-19
- Pfizer’s Ibrance misses the mark in early breast cancer
- Rise of the patient influencer
- Working together against COVID-19
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
PMHub
Valid Insight
Valid Insight is an award-winning pharmaceutical global market access consultancy....
Latest intelligence
- Working together against COVID-19
- Analysing social media conversations to see what HCPs are saying online about the global pandemic...
- Vicky Bramham, Managing Director at OPEN Health PR shares tips on media relations during COVID-19
- Vicky speaks with freelance health journalist Jacqui Thornton who gives her expert view on how best to approach media relations during this unprecedented time....
- Are biobetters a market access opportunity?
- Biobetters are biologics that have been improved compared to the marketed originator, for example in efficacy, safety, tolerability or dosing regimen....
Quick links
Infographics
